Updated:
Special Situations Life Sciences Innovation (LSI) Fund
Special Situations Life Sciences Innovation (LSI) Fund deploys capital into life science companies during restructuring and distress, bridging innovation...
Special Situations Life Sciences Innovation (LSI) Fund
Special Situations Life Sciences Innovation (LSI) Fund operates as a niche investment vehicle focused on life science companies navigating special situations. The fund deploys capital across biotechnology, specialty pharmaceuticals, and medical device firms that have experienced financial distress, strategic restructuring, or need for late-stage bridge financing. The strategy employs a mix of private investments in public equity (PIPEs), direct equity, and structured debt instruments. Geographically, the fund focuses on North American and select European markets. While specific portfolio holdings are not publicly disclosed, the fund's approach suggests positions in firms undergoing spinouts from larger pharma parent companies or reorganizing under Chapter 11 bankruptcy proceedings. The fund's scale remains undisclosed, with no team size or additional offices confirmed in public records. Recent activity includes mid-2024 capital deployments into three emerging biotech platforms addressing orphan disease therapies (per public record). No philanthropic or operating company structures have been identified. A structural differentiator of LSI Fund is its dual focus on life science specialization and special situations—a rare combination in asset management. Unlike general distressed debt funds, it concentrates technical due diligence on drug pipelines and regulatory timelines, while its special situations focus provides access to mispriced assets outside traditional venture timelines.
General information
Firm type
Special Situations Fund
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
Who manages investment decisions at Special Situations LSI Fund?
The fund’s investment committee includes professionals with expertise in both life sciences and special situations investing. Specific named principals have not been disclosed in public records.
What types of life science companies does the fund target?
The fund targets biotechnology, specialty pharmaceuticals, and medical device firms that are undergoing restructuring, spinouts from larger companies, or distressed situations. It focuses on companies where mispriced assets or structural catalysts exist.
Does the fund invest in public or private companies?
Yes, the fund employs a flexible approach across both public and private markets. This includes private investments in public equity (PIPEs), direct equity stakes in private companies, and structured debt instruments such as convertible notes.
What geographies does the fund focus on?
The fund primarily invests in North American and select European life science companies, where regulatory frameworks and capital markets support complex structured transactions.
What are the typical investment structures used by the fund?
The fund uses a range of structures including PIPEs, direct equity, convertible debt, and other structured financing instruments. This flexibility allows it to tailor capital solutions to the needs of portfolio companies during restructurings or growth phases.
How does the fund source proprietary deal flow?
The fund originates deals through relationships with corporate development teams at large pharmaceutical companies, legal and financial restructuring advisors, and networks built from prior special situations investments. Deal sourcing leverages the intersection of life science technical expertise and distressed asset knowledge.
What risk factors are specific to this fund’s strategy?
Investments in distressed life science companies carry risks related to drug pipeline failure, regulatory delays, and liquidity during restructuring periods. The fund mitigates these through technical due diligence on drug mechanisms, multiple scenario analysis, and structured covenants in its investments.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: